- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about RHHBY
Recent news which mentions RHHBY
From Benzinga
From InvestorPlace
From Benzinga
Swiss Healthcare Manufacturing Firm Lonza Bolsters Biologics Manufacturing Capacity With Roche's US Facility Acquisition For $1.2B
March 20, 2024
From Benzinga
FDA Approves BeiGene's First Drug Candidate Produced Through Its Immuno-Oncology Program For Esophageal Cancer
March 15, 2024
From Benzinga
Top Wall Street Analysts Flag US Market Concentration Anxiety, Advise Investors To Adopt 'Barbell Approach'
March 11, 2024
From Benzinga
FDA Conditionally Approves Expanded Use Of BeiGene's Combination Drug For Certain Type Of Blood Cancer
March 08, 2024
From Benzinga
From Benzinga
11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields
February 28, 2024
From Benzinga
This Drug By Roche And Novartis Reduces Allergic Reactions Across Multiple Foods For People With Food Allergies
February 26, 2024
From Benzinga
Move Over Magnificent 7, Say Hello to the GRANOLAS
February 22, 2024
From InvestorPlace
FDA Fast-Tracks Review Of Sarepta's Groundbreaking Muscular Dystrophy Treatment With $1B Market In Sight
February 16, 2024
From Benzinga
Monte Rosa Therapeutics' AI And Machine Learning Platform Is Adding Significant Value Creation in Cancer Research: Analyst
February 15, 2024
From Benzinga
Roche Terminates Cancer Drug Pact With Repare Therapeutics, Its Second Walkout Within A Month
February 13, 2024
From Benzinga
From Benzinga
Roche's One Of Largest Selling Cancer Drug Approved Under The Skin Injection Version In Europe
January 16, 2024
From Benzinga
Merck's Crown Jewel Cancer Drug Keytruda Scores FDA Approval For Third Indication In Cervical Cancer
January 16, 2024
From Benzinga
Is AI More Valuable In Advertising Than Healthcare? Jim Cramer Questions Wall Street's Preference
January 10, 2024
From Benzinga
2 Growth Stocks That Could Make You Richer in 2024 and Beyond
January 09, 2024
From Motley Fool
Why Is LumiraDx (LMDX) Stock Down 13% Today?
January 08, 2024
From InvestorPlace
3 Great Foreign Companies to Invest in Right Now
January 08, 2024
From Motley Fool
Roche Agrees To Purchase Part Of COVID-19 Test Player LumiraDx Diagnostics Platform For $295M
January 02, 2024
From Benzinga
Weighing Their Chances: 5 Leading Healthcare Companies Fight for Market Share in the $100 Billion Weight-Loss Industry
December 21, 2023
From Motley Fool
Calliditas Therapeutics Scores Complete FDA Approval, Broader Label For Lead Kidney Disease Drug
December 21, 2023
From Benzinga
This Big Pharma Is Teaming Up With Nvidia to Make Drugs With AI. Here's What You Need to Know
December 20, 2023
From Motley Fool
Weight-Loss Drug Gold Rush Gets Larger As New Player Fractyl Health Files For $100M IPO
December 15, 2023
From Benzinga
The 3 Most Undervalued Biotech Stocks to Buy in December
December 15, 2023
From InvestorPlace
Poseida Therapeutics' New Treatment For Multiple Myeloma Shows Early Success In Clinical Trial
December 11, 2023
From Benzinga
Why Viking Therapeutics Was Crushing It This Week
December 08, 2023
From Motley Fool
From MarketWatch
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.